metoprolol has been researched along with Benign Neoplasms in 6 studies
Metoprolol: A selective adrenergic beta-1 blocking agent that is commonly used to treat ANGINA PECTORIS; HYPERTENSION; and CARDIAC ARRHYTHMIAS.
metoprolol : A propanolamine that is 1-(propan-2-ylamino)propan-2-ol substituted by a 4-(2-methoxyethyl)phenoxy group at position 1.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Fedratinib is a weak inhibitor of CYP2D6, and a moderate inhibitor of CYP2C19 and CYP3A4." | 2.94 | Assessment of effects of repeated oral doses of fedratinib on inhibition of cytochrome P450 activities in patients with solid tumors using a cocktail approach. ( Krishna, G; LoRusso, PM; Ogasawara, K; Olszanski, AJ; Palmisano, M; Rixe, O; Xu, C; Yin, J, 2020) |
| "When gefitinib was administered in the presence of itraconazole, gmean AUC increased by 78% and 61% at gefitinib doses of 250 and 500 mg, respectively; these changes also being statistically significant." | 2.71 | Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol. ( Laight, A; Leadbetter, J; McKillop, D; Ranson, M; Smith, RP; Swaisland, HC; Wild, MJ, 2005) |
| "HIF-1 activity in tumors depends on availability of the HIF-1α subunit, the levels of which increase under hypoxic conditions and through activation of oncogenes and/or inactivation of tumor suppressor genes." | 2.48 | Recent advances in hypoxia-inducible factor (HIF)-1 inhibitors. ( Choi, HK; Lee, K; Xia, Y, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Choi, E | 1 |
| Lee, C | 1 |
| Park, JE | 1 |
| Seo, JJ | 1 |
| Cho, M | 1 |
| Kang, JS | 1 |
| Kim, HM | 1 |
| Park, SK | 1 |
| Lee, K | 2 |
| Han, G | 1 |
| Xia, Y | 1 |
| Choi, HK | 1 |
| Ogasawara, K | 1 |
| LoRusso, PM | 1 |
| Olszanski, AJ | 1 |
| Rixe, O | 1 |
| Xu, C | 1 |
| Yin, J | 1 |
| Palmisano, M | 1 |
| Krishna, G | 1 |
| Friedman, GD | 1 |
| Udaltsova, N | 1 |
| Habel, LA | 1 |
| Swaisland, HC | 1 |
| Ranson, M | 1 |
| Smith, RP | 1 |
| Leadbetter, J | 1 |
| Laight, A | 1 |
| McKillop, D | 1 |
| Wild, MJ | 1 |
| Noori, A | 1 |
| Lindenfeld, J | 1 |
| Wolfel, E | 1 |
| Ferguson, D | 1 |
| Bristow, MR | 1 |
| Lowes, BD | 1 |
1 review available for metoprolol and Benign Neoplasms
| Article | Year |
|---|---|
Recent advances in hypoxia-inducible factor (HIF)-1 inhibitors.
Topics: Animals; Antineoplastic Agents; Drug Discovery; Gene Expression Regulation, Neoplastic; Humans; Hypo | 2012 |
2 trials available for metoprolol and Benign Neoplasms
| Article | Year |
|---|---|
Assessment of effects of repeated oral doses of fedratinib on inhibition of cytochrome P450 activities in patients with solid tumors using a cocktail approach.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cross | 2020 |
Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol.
Topics: Adolescent; Adult; Antineoplastic Agents; Cross-Over Studies; Cytochrome P-450 CYP2D6; Cytochrome P- | 2005 |
3 other studies available for metoprolol and Benign Neoplasms
| Article | Year |
|---|---|
Structure and property based design, synthesis and biological evaluation of γ-lactam based HDAC inhibitors.
Topics: Animals; Antineoplastic Agents; Binding Sites; Cell Line, Tumor; Cell Membrane Permeability; Compute | 2011 |
Norepinephrine antagonists and cancer risk.
Topics: Atenolol; Breast Neoplasms; Clonidine; Colonic Neoplasms; Female; Humans; Lung Neoplasms; Male; Meto | 2011 |
Beta-blockade in adriamycin-induced cardiomyopathy.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Antineoplastic Agents; Carbazoles; Cardiomyopathies; Cardi | 2000 |